Gilead Sciences (GILD) Earns Daily News Sentiment Score of 2.17

Media coverage about Gilead Sciences (NASDAQ:GILD) has been trending positive on Friday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than 6,000 news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Gilead Sciences earned a media sentiment score of 2.17 on their scale. InfoTrie also assigned media coverage about the biopharmaceutical company an news buzz score of 6 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company’s share price in the near term.

These are some of the headlines that may have effected Gilead Sciences’ ranking:

Shares of GILD stock opened at $70.19 on Friday. Gilead Sciences has a 52-week low of $64.27 and a 52-week high of $89.54. The company has a quick ratio of 3.37, a current ratio of 3.45 and a debt-to-equity ratio of 1.09. The firm has a market capitalization of $89.97 billion, a price-to-earnings ratio of 8.20, a price-to-earnings-growth ratio of -2.70 and a beta of 1.01.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.63 by $0.21. Gilead Sciences had a return on equity of 39.32% and a net margin of 7.12%. The business had revenue of $5.60 billion during the quarter, compared to analyst estimates of $5.44 billion. During the same quarter in the prior year, the business posted $2.27 EPS. Analysts expect that Gilead Sciences will post 6.44 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 28th. Shareholders of record on Friday, December 14th will be paid a $0.57 dividend. The ex-dividend date is Thursday, December 13th. This represents a $2.28 dividend on an annualized basis and a yield of 3.25%. Gilead Sciences’s payout ratio is presently 26.64%.

A number of equities research analysts have weighed in on GILD shares. Cantor Fitzgerald boosted their target price on shares of Gilead Sciences from $87.00 to $88.00 and gave the company an “overweight” rating in a research note on Friday, October 26th. BidaskClub upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, November 8th. Zacks Investment Research lowered Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 25th. Raymond James reduced their price objective on Gilead Sciences from $97.00 to $94.00 and set a “strong-buy” rating for the company in a research note on Friday, October 26th. Finally, Barclays upped their price objective on Gilead Sciences from $90.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, October 26th. Eleven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Gilead Sciences presently has a consensus rating of “Buy” and a consensus price target of $88.63.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $69.55, for a total value of $3,477,500.00. Following the completion of the sale, the director now owns 3,067,762 shares in the company, valued at approximately $213,362,847.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 150,000 shares of company stock valued at $10,939,500 in the last quarter. 1.30% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Gilead Sciences (GILD) Earns Daily News Sentiment Score of 2.17” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Featured Article: Why do company’s buyback their stock?

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with's FREE daily email newsletter.

Leave a Reply